Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ekaterine Arkania"'
Autor:
Ying, Cheng, Liang, Han, Lin, Wu, Jun, Chen, Hongmei, Sun, Guilan, Wen, Yinghua, Ji, Mikhail, Dvorkin, Jianhua, Shi, Zhijie, Pan, Jinsheng, Shi, Xicheng, Wang, Yuansong, Bai, Tamar, Melkadze, Yueyin, Pan, Xuhong, Min, Maksym, Viguro, Xingya, Li, Yanqiu, Zhao, Junquan, Yang, Tamta, Makharadze, Ekaterine, Arkania, Wenying, Kang, Qingyu, Wang, Jun, Zhu, Denys, Pominchuk
Publikováno v:
JAMA. 328(12)
Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC). It remained unknown whether adding a programmed cell death 1 (PD-1)
Autor:
Mafalda Oliveira, Denys Pominchuck, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Yuriy Semegen, Vladmir Vladmirov, Claudio Zamagni, Hannelore Denys, Frederic Forget, Zsolt Horvath, Alfiya Nesterova, Maxine Bennett, Bistra Kirova, Teresa Klinowska, Justin Lindemann, Delphine Lissa, Alastair Mathewson, Christopher Morrow, Zuzana Traugottova, Ruaan Van Zyl, Ekaterine Arkania
Publikováno v:
Cancer Research. 83:GS3-02
Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in ER+ breast cancer (BC) in the Phase 1 SERENA-1 study1,2 with a dose-dependent safety profil
Autor:
Giada Rizzi, Lee S. Schwartzberg, Rebecca Clark-Snow, Ekaterine Arkania, Richard J. Gralla, Rudolph M. Navari, Matti Aapro, Daniel Voisin, Rita Wickham, Irena Radyukova, Kamal Patel, Eric Roeland
Publikováno v:
The Oncologist
Background NEPA, a combination antiemetic of a neurokinin‐1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT3RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution co
Autor:
Ekaterine Arkania, Nino Chichua
Publikováno v:
The Breast. 36:S54-S55